While average numbers are not always useful, it is worth mentioning that out of the 20 HoldCos und...
Medtechs are going nowhere. The post Covid darlings are no longer much in demand.
With much of Sandoz’s upside already captured, betting on Hikma’s (albeit still nascent) growth in its...
AlphaValue maintains its cautious stance when it comes to tariff friction costs on both sides of the po...
All of a sudden Telcos are as expensive as the broader market. This is news.